Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms.
The association of high mobility group (HMG) proteins with cisplatin-damaged DNA has attracted considerable interest because of a possible relationship with drug-acquired resistance and the repair of DNA damage caused by this important chemotherapeutic agent. We have further characterized the binding of HMG proteins to cisplatin-damaged DNA using a modification of the damaged DNA affinity precipitation assay (DDAP) and proteins isolated from the nuclei of V79 cells. HMG proteins recognized cisplatin adducts only in double-stranded DNA sequences. Pre-treatment of cells with cisplatin (1 microM) prior to protein extraction decreased the apparent yield of HMG proteins. However, the pre-treatment of isolated protein did not prevent recognition of the DNA adducts. To investigate the possible role of HMG proteins in toxicity and resistance, we have extended the DDAP method to study other platinum agents, some of which are active in cisplatin-resistant cells. A comparison of trans- and cis-[PtCl2(NH3)quinoline] is presented as an example. HMG proteins recognized DNA damage caused by the cis, but not the trans isomer. However, the trans isomer is known to be significantly more toxic and is highly active in cisplatin-resistant cells, suggesting a mechanism of action different from cisplatin. Therefore, the toxicity of trans-[PtCl2(NH3)quinoline] appears to be unrelated to the recognition of damage by HMG proteins. The DDAP assay may provide an additional screen for new mechanisms of cytotoxic platinum agents.
Marples
B
B
Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, Canada.
Adomat
H
H
Billings
P C
PC
Farrell
N P
NP
Koch
C J
CJ
Skov
K A
KA
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000633:toxicity*; D002417:Cattle; D002460:Cell Line; D002945:Cisplatin / Q000633:toxicity; D006224:Cricetinae; D003412:Cricetulus; D004247:DNA / Q000187:drug effects* / Q000378:metabolism*; D004249:DNA Damage; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004351:Drug Resistance; D006609:High Mobility Group Proteins / Q000378:metabolism*; D007536:Isomerism; D009944:Organoplatinum Compounds / Q000378:metabolism* / Q000633:toxicity*; D012680:Sensitivity and Specificity
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D006609:High Mobility Group Proteins; D009944:Organoplatinum Compounds; D004247:DNA; D002945:Cisplatin